Case reports in infectious diseases · 2026
HIV-Associated Diffuse Large B-Cell Lymphoma Treated With Outpatient Pola-R-CHP Without Antiretroviral Therapy Modification: A Case Report.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ikoma Yoshikazu, Ishihara Masashi, Sugiyama Hitomi, Okamoto Daisuke, Hayase Naoki, Yamaguchi Kimihiro, Matsumoto Takuro, Tetsuka Nobuyuki, Nakamura Nobuhiko, Nakamura Hiroshi, Kanemura Nobuhiro, Shimizu Masahito, Tsurumi Hisashi
Аннотация
INTRODUCTION: People living with HIV (PLWH) remain at increased risk of diffuse large B-cell lymphoma (DLBCL). Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) has emerged as a standard first-line option for DLBCL in the general population, but the pivotal POLARIX trial excluded PLWH, leaving limited evidence on feasibility with contemporary antiretroviral therapy (ART).
CASE PRESENTATION: A 61-year-old man presented with progressive anorexia and weight loss. With durable virologic suppression (plasma HIV-1 RNA below 20 copies/mL) and immune reconstitution (CD4+ T-cell count approximately 300 cells/µL) on bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), he was diagnosed with nongerminal center B-cell DLBCL (Lugano stage II; International Prognostic Index score 2). Pola-R-CHP was administered every 21 days for six cycles (Cycle 1: inpatient and Cycles 2-6: outpatient), followed by two additional rituximab cycles, without ART modification. No grade 3-4 nonhematologic toxicity, febrile neutropenia, or serious infections occurred. HIV-1 RNA remained below 20 copies/mL throughout treatment, and CD4+ T-cell counts showed no clinically meaningful decline. End-of-treatment fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET-CT) demonstrated a partial metabolic response with two small residual FDG-avid foci (∼1 cm; SUVmax ∼4-5). At the last follow-up, the patient had no clinical or radiologic evidence of progression.
CONCLUSION: Outpatient-delivered Pola-R-CHP appeared feasible in PLWH with virologic suppression and immune reconstitution receiving BIC/FTC/TAF, without virologic breakthrough or unexpected toxicity. Prospective inclusion of PLWH in polatuzumab-containing frontline studies is warranted.
CASE PRESENTATION: A 61-year-old man presented with progressive anorexia and weight loss. With durable virologic suppression (plasma HIV-1 RNA below 20 copies/mL) and immune reconstitution (CD4+ T-cell count approximately 300 cells/µL) on bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), he was diagnosed with nongerminal center B-cell DLBCL (Lugano stage II; International Prognostic Index score 2). Pola-R-CHP was administered every 21 days for six cycles (Cycle 1: inpatient and Cycles 2-6: outpatient), followed by two additional rituximab cycles, without ART modification. No grade 3-4 nonhematologic toxicity, febrile neutropenia, or serious infections occurred. HIV-1 RNA remained below 20 copies/mL throughout treatment, and CD4+ T-cell counts showed no clinically meaningful decline. End-of-treatment fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET-CT) demonstrated a partial metabolic response with two small residual FDG-avid foci (∼1 cm; SUVmax ∼4-5). At the last follow-up, the patient had no clinical or radiologic evidence of progression.
CONCLUSION: Outpatient-delivered Pola-R-CHP appeared feasible in PLWH with virologic suppression and immune reconstitution receiving BIC/FTC/TAF, without virologic breakthrough or unexpected toxicity. Prospective inclusion of PLWH in polatuzumab-containing frontline studies is warranted.